Eli Lilly touts MACE win for diabetes blockbuster Trulicity — a 'nice positive'
Eli Lilly $LLY is boasting about a big win for its blockbuster diabetes drug Trulicity, saying their drug produced “compelling” evidence of its ability to guard against cardio events.
We don’t have the data yet, but the pharma giant is saying it’s clear that Trulicity delivers in preventing initial or secondary major cardio events like heart attacks. And it did it in a study with only a minority of at-risk patients, which will perhaps help distinguish it from the crowd of GLP-1 drugs now on the market, which have their own MACE data to tout.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
